Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)
Public ClinicalTrials.gov record NCT04949256. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared With Standard of Care as First-line Intervention in Participants With Metastatic Esophageal Carcinoma
Study identification
- NCT ID
- NCT04949256
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Enrollment
- 864 participants
Conditions and interventions
Interventions
- 5-FU Drug
- Cisplatin Drug
- Lenvatinib Drug
- Leucovorin Drug
- Levoleucovorin Drug
- Oxaliplatin Drug
- Paclitaxel Drug
- Pembrolizumab Biological
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 27, 2021
- Primary completion
- May 7, 2025
- Completion
- Jun 11, 2026
- Last update posted
- Dec 14, 2025
2021 – 2026
United States locations
- U.S. sites
- 15
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope ( Site 0102) | Duarte | California | 91010 | — |
| MedStar Washington Hospital Center ( Site 0186) | Washington D.C. | District of Columbia | 20010 | — |
| James Graham Brown Cancer Center ( Site 0117) | Louisville | Kentucky | 40202 | — |
| Norton Cancer Institute ( Site 0116) | Louisville | Kentucky | 40217 | — |
| Johns Hopkins Bayview Medical Center ( Site 0152) | Baltimore | Maryland | 21224 | — |
| UMASS Memorial Medical Center ( Site 0120) | Worcester | Massachusetts | 01655 | — |
| Capital Health Medical Center - Hopewell ( Site 0189) | Pennington | New Jersey | 08534 | — |
| Hematology-Oncology Associates of CNY ( Site 0173) | East Syracuse | New York | 13057 | — |
| Memorial Sloan Kettering Cancer Center ( Site 0132) | New York | New York | 10065 | — |
| Weill Cornell Medical College ( Site 0133) | New York | New York | 10065 | — |
| St. Luke's University Health Network ( Site 0185) | Bethlehem | Pennsylvania | 18015 | — |
| AHN Allegheny General Hospital ( Site 0164) | Pittsburgh | Pennsylvania | 15212 | — |
| Medical University of South Carolina-Hollings Cancer Center ( Site 0177) | Charleston | South Carolina | 29425 | — |
| VCU Health Adult Outpatient Pavillion ( Site 0160) | Richmond | Virginia | 23219 | — |
| Seattle Cancer Care Alliance ( Site 0145) | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 183 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04949256, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 14, 2025 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04949256 live on ClinicalTrials.gov.